The Moffitt requests $248,588 in annual direct costs for support of Administration personnel, totaling 2.10 FTE. The budget request represents less than 4% of the total CCSG request and is less than 1% of Moffitt's total Research Administration operational budget. Since all research activities at Moffitt are cancer-related, support of research is in direct support of the Cancer Center Support Grant and is composed of three primary functions: Program Administration, Shared Resource Oversight, and Research Administration. Program administrative support is provided at the division level (Basic Science, Prevention &Control, Translational Science, and Clinical Investigations) with dedicated staff led by a Division Administrator who provides support for the programs and faculty within their division. Shared Resource Oversight occurs through alignment and allocation of functions to specific administrative groups: Laboratory Operations;Clinical Trials Office;Tissue;and Cell Therapies. Research Administration represents a collection of Offices that provide a range of support activities including: Institutional Support Services;Sponsored Research;Grant and Contract Accounting;Research Costs Analysis;Clinical Trials Finance;Protocol Review and Support;and Institutional Regulatory Affairs. The administration of research activities for the Cancer Center is organized under Michael Benedict, PharmD, who reports to Dr. Dalton through the Director of the Moffitt Research Institute (MRI) and Associate Center Director for Cancer Prevention and Control, Dr. Sellers. In addition to reporting to the Director of the MRI, Dr. Benedict has functional responsibilities to all Associate Center Directors. Leadership has changed since the last submission. Dr. Benedict, was recruited back to the Cancer Center to serve as Vice President for Clinical Investigations, and in July 2009, was appointed the sole Vice President for Research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA076292-15W2
Application #
8723481
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$49,999
Indirect Cost
$20,326
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303
Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612
Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53
Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880
Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73
Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :
Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :
Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029
Robinson, Lary A; Jaing, Crystal J; Pierce Campbell, Christine et al. (2016) Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung. Br J Cancer 115:497-504

Showing the most recent 10 out of 974 publications